| Robyn Lynn Boedefeld, MD | |
|
7777 Hennessy Blvd, Suite 701, Baton Rouge, LA 70808-4300 | |
| (225) 765-5864 | |
| (225) 765-2013 |
| Full Name | Robyn Lynn Boedefeld |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 25 Years |
| Location | 7777 Hennessy Blvd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467407577 | NPI | - | NPPES |
| 009991735 | Medicaid | AL | |
| P00267754 | Other | AL | RAILROAD MEDICARE |
| 1167584 | Medicaid | LA | |
| 010293171 | Medicaid | VA | |
| 051528036 | Other | AL | BLUE CROSS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Medical Center - Baton Rouge | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayfair Physician Services, Llc | 7618225814 | 36 |
News Archive
Kidney Health Australia (KHA) has released a report that predicts that the number of people needing treatment for serious kidney disease will triple to 30,000 by 2020 and treating serious kidney disease will cost the health system $12 billion over the next decade. The report, by the George Institute for Global Health, also found the annual cost of providing dialysis treatment was just over $79,000 per patient. This was compared to just over $49,000 per person taking part in a program which delivers the treatment not in a hospital but in the patient's home.
The increased consumption of glucose that tumour cells exhibit, was thought to be a cause of the extra demand of building blocks required to keep up with an uncontrolled cell growth, but now it is more accepted that it could be the effect of a programmed metabolic change that favours this malignant growth.
DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.
For patients with end stage renal disease (ESRD) on dialysis who also must be treated for heart disease, stents provide the best one-year survival compared with other revascularization treatments, but bypass surgery provides the best long-term survival, according to a paper being presented at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.
› Verified 6 days ago
| Entity Name | Mayfair Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831688365 PECOS PAC ID: 7618225814 Enrollment ID: O20180803002194 |
News Archive
Kidney Health Australia (KHA) has released a report that predicts that the number of people needing treatment for serious kidney disease will triple to 30,000 by 2020 and treating serious kidney disease will cost the health system $12 billion over the next decade. The report, by the George Institute for Global Health, also found the annual cost of providing dialysis treatment was just over $79,000 per patient. This was compared to just over $49,000 per person taking part in a program which delivers the treatment not in a hospital but in the patient's home.
The increased consumption of glucose that tumour cells exhibit, was thought to be a cause of the extra demand of building blocks required to keep up with an uncontrolled cell growth, but now it is more accepted that it could be the effect of a programmed metabolic change that favours this malignant growth.
DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.
For patients with end stage renal disease (ESRD) on dialysis who also must be treated for heart disease, stents provide the best one-year survival compared with other revascularization treatments, but bypass surgery provides the best long-term survival, according to a paper being presented at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robyn Lynn Boedefeld, MD 7777 Hennessy Blvd, Suite 701, Baton Rouge, LA 70808-4300 Ph: (225) 765-5864 | Robyn Lynn Boedefeld, MD 7777 Hennessy Blvd, Suite 701, Baton Rouge, LA 70808-4300 Ph: (225) 765-5864 |
News Archive
Kidney Health Australia (KHA) has released a report that predicts that the number of people needing treatment for serious kidney disease will triple to 30,000 by 2020 and treating serious kidney disease will cost the health system $12 billion over the next decade. The report, by the George Institute for Global Health, also found the annual cost of providing dialysis treatment was just over $79,000 per patient. This was compared to just over $49,000 per person taking part in a program which delivers the treatment not in a hospital but in the patient's home.
The increased consumption of glucose that tumour cells exhibit, was thought to be a cause of the extra demand of building blocks required to keep up with an uncontrolled cell growth, but now it is more accepted that it could be the effect of a programmed metabolic change that favours this malignant growth.
DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.
For patients with end stage renal disease (ESRD) on dialysis who also must be treated for heart disease, stents provide the best one-year survival compared with other revascularization treatments, but bypass surgery provides the best long-term survival, according to a paper being presented at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.
› Verified 6 days ago
Dr. Jennifer L Rippon, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7777 Hennessy Blvd Ste 409, Baton Rouge, LA 70808 Phone: 225-765-5864 Fax: 225-765-2013 | |
Gregory Fusilier, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 9103 Jefferson Hwy, Baton Rouge, LA 70809 Phone: 225-927-1190 Fax: 225-927-0988 | |
Dr. Yolanda Maria O'rourke, Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 7968 Essen Park, Baton Rouge, LA 70809 Phone: 225-761-6700 Fax: 225-761-6760 | |
Patricia D. Whatley, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Attn: Dee / Administration, Baton Rouge, LA 70808 Phone: 225-769-4044 | |
Frederick Cerise, Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3810 W Lakeshore Dr, Baton Rouge, LA 70808 Phone: 225-578-8886 | |
Dr. Jon Richard Jackson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5000 Hennessy Blvd, Baton Rouge, LA 70808 Phone: 225-765-4050 Fax: 225-765-4046 | |
Richard Frank Burroughs, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: Earl K. Long Hospital, Lsu Unit, 5825 Airline Highway, Baton Rouge, LA 70805 Phone: 225-358-3938 |